Hematopoietic Adverse Events Associated with BNT162b2 mRNA Covid-19 Vaccine

Creative Commons License

Erdogdu B., ÇINAR O. E., Malkan Ü. Y., AKSU S., DEMİROĞLU H., BÜYÜKAŞIK Y., ...Daha Fazla

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.32, sa.1, ss.65-67, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Kısa Makale
  • Cilt numarası: 32 Sayı: 1
  • Basım Tarihi: 2022
  • Doi Numarası: 10.4999/uhod.226097
  • Dergi Adı: UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.65-67
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Our second case is a 49-year-old female patient, two days after receiving BNT162b2 mRNA COVID-19 vaccine, petechiae was started in arms and then in lower extremities. The complaints of weakness and fatigue continued to increase within days. The patient, who was admitted to the hospital ten days later with these complaints, was found to have bi-cytopenia. Bone marrow aspiration and biopsy reported that 20-30% stained with cd19 diffuse positive Terminal deoxynucleotidyl transferase (TdT) in blastic cells. HyperCVAD chemotherapy was started with the diagnosis of b-acute lymphoOur third case is a 57-year-old male patient, difficulty in swallowing, and oral ulceration after vaccination of BNT162b2 mRNA COVID-19 vac